Xeris Biopharma Holdings (XERS) Other Operating Expenses (2020 - 2026)

Xeris Biopharma Holdings (XERS) has 7 years of Other Operating Expenses data on file, last reported at $13.3 million in Q1 2026.

• Quarterly Other Operating Expenses rose 16.14% year-over-year to $13.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $55.3 million (up 9.57% YoY) and the FY2025 annual result came in at $53.4 million, up 12.03% from the prior year.
• Other Operating Expenses retreated to $13.3 million in Q1 2026, from $13.7 million in the prior quarter.
• In the past five years, Other Operating Expenses ranged from a high of $16.3 million in Q3 2024 to a low of $7.5 million in Q2 2022.
• A 5-year average of $11.0 million and a median of $10.5 million in 2024 frame the typical range for Other Operating Expenses.
• Annual changes were most pronounced in 2022 — Other Operating Expenses surged 392.0% — and 2025, when it retreated 15.93%.
• Tracing XERS's Other Operating Expenses over 5 years: stood at $9.0 million in 2022, then increased by 14.21% to $10.3 million in 2023, then increased by 18.56% to $12.2 million in 2024, then rose by 12.05% to $13.7 million in 2025, then declined by 2.74% to $13.3 million in 2026.
• The last three Other Operating Expenses figures came in at $13.3 million (Q1 2026), $13.7 million (Q4 2025), and $13.7 million (Q3 2025), per Business Quant data.